Movement Alert｜Recursion Pharmaceuticals, Inc. falls 5.11% in Regular Trading, market continues to reassess REC-4881 registrational trial path after data-driven rally fades

Market Focus00:19

On November 14, Recursion Pharmaceuticals, Inc. fell 5.11% in Regular Trading, trading at $3.165 per share, with turnover of $20.9625 million.

The clearest catalyst cited in recent market updates is that enthusiasm following the company’s REC-4881 Phase 2 update has continued to fade, with investors shifting back to evaluating the timing and prospects of a registrational trial and the room for valuation recovery.

Recent company disclosures said REC-4881 showed meaningful reductions in polyp burden in familial adenomatous polyposis patients, alongside a relatively clean safety profile that supports advancing toward a registrational study. Separately, Recursion Pharmaceuticals, Inc. reported quarterly revenue of $18.552 million, above the $14.783 million consensus estimate, while EPS was a loss of $0.22.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment